Combined T cell checkpoint blockade to eradicate established cancer

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/1059862

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

We will use combinations of antibodies to rescue exhausted immune effector T cells in cancers or deplete those T cells that suppress tumor immunity. These exciting new approaches have potential curative impact for the treatment of many human cancers. The mouse has been a useful predictive model and in mice, we will aim to study the combinatorial efficacy and mechanism of action of the most promising antibodies and design a new and more specific means to deplete intratumor regulatory T cells.

Funded Activity Details

Start Date: 01-01-2014

End Date: 01-01-2016

Funding Scheme: Project Grants

Funding Amount: $207,588.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Cancer Therapy (excl. Chemotherapy and Radiation Therapy)

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

T cell immunity | antibody cancer therapy | immunomodulation | immunosuppression | immunotherapy

Related Links